Playwright Paul Mullin found an unexpected audience for his play “The Sequence,” which is about the competition to sequence the human genome. He started hearing from biotech organizations interested in hosting readings of the play at symposiums and meetings around the country.
This was before he even had a final draft!
What’s more, he found that these organizations would pay well for it. Significantly more than theaters would. Which makes sense, because biotech organizations have a lot more money than theaters, even during a recession.
You can read his blog post about this at When Plays Pay in Odd Ways.
So, what other organizations, besides theaters, might like a play about nuns who make moonshine? I’m going to start thinking about this.
How about your plays? Who else might like them? And who would be able to pay well?